PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference

BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, taking place on March 19-22, 2023 in Dallas, Texas.

PepGen intends to issue a press release concurrent with the conclusion of the Company’s presentations, and plans to post the poster presentation and data presentations on the Events and Presentations page in the Investor Relations section of the company’s website.

Podium Presentations:

Title: Positive Results from a First-in-Human Study Support Continued Development of PGN EDO51 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Abstract Number: #95
Session Topic: Clinical Trials
Date & Time: Wednesday, March 22, 2023 at 3:00pm ET
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development

Title: PGN-EDODM1 Nonclinical Data Demonstrate Potential for Meaningful Impact in Myotonic Dystrophy Type 1 (DM1): Support for Phase 1 Clinical Trial Design
Abstract Number: #306
Session Topic: Translational Research
Date & Time: Wednesday, March 22, 2023 at 10:15am ET
Presenter: Jane Larkindale, Ph.D., Vice President, Clinical Science

Poster Presentation:

Title: Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Abstract Number: #242
Session Topic: Preclinical Research
Date & Time: Poster presentation available throughout the conference from March 19-22, 2023
Presenter: Ashling Holland, Ph.D., Director of Preclinical Development

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the ongoing Phase 1 study of PGN-EDO51, the filing of an IND application for PGN-EDODM1, the reporting of non-human primate data for PGN-EDO53 and the nomination of development candidates; and statements about our clinical and preclinical programs, product candidates, expected cash runway, achievement of milestones, and corporate and clinical/preclinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1 trial for EDO51 and preclinical studies of other product candidates or to obtain regulatory approval before commercialization for marketing of such products; our product candidates may not be safe and effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; we may not be able to nominate new drug candidates within the estimated timeframes; our estimation of addressable markets of our product candidates may be inaccurate; we may need additional funding before the end of our expected cash runway and may fail to timely raise such additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com  

Media Contact
Gwendolyn Schanker
LifeSci Communications
gschanker@lifescicomms.com